Status:
RECRUITING
A Direct-to-Consumer Study Investigating the Effect of Specific Cannabinoid Products on Motivation, Energy Level, Focus, and Appetite in Healthy Adults
Lead Sponsor:
Phylos Bioscience, Inc.
Collaborating Sponsors:
People Science, Inc.
Conditions:
Motivation
Eligibility:
All Genders
21-100 years
Brief Summary
Tetrahydrocannabivarin (THCV) is a rare cannabinoid and is a homologue of THC that differs only in the length of the alkyl side chain (3C vs 5C, respectively). Pre-clinical and clinical trials have sh...
Detailed Description
The rationale for this study is to determine the effect of a consumer-grade, state-legal formulation of cannabinoids including Tetrahydrocannabivarin (THCV) on motivation, energy level, focus, and app...
Eligibility Criteria
Inclusion
- Healthy adults age \> 21 years old
- Work / study / play in an environment that requires focus
- Able to read and understand English
- Able to read, understand, and provide informed consent
- Able to use a personal smartphone device and download Chloe by People Science
- Able to complete study assessments over the course of up to 14 days
- Familiar with the use of cannabis and its effects
- Able to tolerate at least 5mg THC
- Willingness to abstain from use of any THC containing products during study product use days
- Willingness to abstain from use of alcohol during study product use days
- Greater Los Angeles area residents only
Exclusion
- Participants who do not have a smartphone and/or internet access
- Any known adverse effects from taking cannabis
- Concomitant Therapies: Currently taking medication for ADHD or psychotropic medications
- Other Illnesses or Conditions: Participants who have the following co-morbidities are excluded:
- History or currently undergoing product use for substance abuse disorders
- Currently pregnant, planning to become pregnant within the next month, or breastfeeding
- Allergies to formulation ingredients
- Current or prior psychotic disorder
- Immunosuppressive product uses, including organ transplant participants, active immunotherapy for cancer product use
- Any condition that is considered by investigator to be a contraindication to cannabis (e.g. specific drug-use interaction, unstable cardiac arrhythmia)
Key Trial Info
Start Date :
August 14 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT06213064
Start Date
August 14 2023
End Date
June 1 2024
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
People Science, Inc.
Los Angeles, California, United States, 90034